2005•Journal of Functional BiomaterialsOpen access

Experiment study on hydroxyapatite bone cement as a slow-release carrier of bioactive factor

Zhang Cai-xia

Open full text 0 citations

Abstract

To investigate the validity of hydroxyapatite bone cement (HAC) as a slow-release carrier of bioactive factor. Experimental samples were divided to three groups:(1) Part drug group: the hydroxyapatite bone cement/norvancomyicn (HAC/NVCM) compound was implanted to tibiae of rabbit. (2)Total body drug group: the hydroxyapatite bone cement without NVCM were implanted to tibiae of rabbit, NVCM were injectived from the oto vein of rabbit. Then the drug concentrations were determined in blood and bone of animals at a series different time.(3) BMP group:After prepare of the HAC/rhBMP-2 compounds, witch were implanted to latissimus dorsal muscle pouches of rabbit, then dystopy induction of bone were viewed at 4 weeks. The experiment Results show that the drug concentrations of Part drug group in blood were all lower than that of Total body drug group at every time. But the drug concentration of Part drug group in bone were marked higher than that of Total body drug group, even at 2 weeks,the drug concentration had still 3.96μg/mg. On the surface of the HAC/rhBMP-2 compounds, the new build bone could be observed. As a slow-release carrier of drug and BMP, HAC throw out a good release characteristic.

About this research paper

What this paper is about

To investigate the validity of hydroxyapatite bone cement (HAC) as a slow-release carrier of bioactive factor. Experimental samples were divided to three groups:(1) Part drug group: the hydroxyapatite bone cement/norvancomyicn (HAC/NVCM) compound was implanted to tibiae of rabbit. (2)Total body drug group: the hydroxyapatite bone cement without NVCM were implanted to tibiae of rabbit, NVCM were injectived from the oto vein of rabbit. Then the drug concentrations were determined in blood and bone of animals at a series different time.(3) BMP group:After prepare of the HAC/rhBMP-2 compounds, witch were implanted to latissimus dorsal muscle pouches of rabbit, then dystopy induction of bone were viewed at 4 weeks. The experiment Results show that the drug concentrations of Part drug group in blood were all lower than that of Total body drug group at every time. But the drug concentration of Part drug group in bone were marked higher than that of Total body drug group, even at 2 weeks,the drug concentration had still 3.96μg/mg. On the surface of the HAC/rhBMP-2 compounds, the new build bone could be observed. As a slow-release carrier of drug and BMP, HAC throw out a good release characteristic.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To investigate the validity of hydroxyapatite bone cement (HAC) as a slow-release carrier of bioactive factor. Experimental samples were divided to three groups:(1) Part drug group: the hydroxyapatite bone cement/norvancomyicn (HAC/NVCM) compound was implanted to tibiae of rabbit. (2)Total body drug group: the hydroxyapatite bone cement without NVCM were implanted to tibiae of rabbit, NVCM were injectived from the oto vein of rabbit. Then the drug concentrations were determined in blood and bone of animals at a series different time.(3) BMP group:After prepare of the HAC/rhBMP-2 compounds, witch were implanted to latissimus dorsal muscle pouches of rabbit, then dystopy induction of bone were viewed at 4 weeks. The experiment Results show that the drug concentrations of Part drug group in blood were all lower than that of Total body drug group at every time. But the drug concentration of Part drug group in bone were marked higher than that of Total body drug group, even at 2 weeks,the drug concentration had still 3.96μg/mg. On the surface of the HAC/rhBMP-2 compounds, the new build bone could be observed. As a slow-release carrier of drug and BMP, HAC throw out a good release characteristic.

Key concepts: Bone cement, Drug, Materials science, Cement, Biomedical engineering, Pharmacology, Chemistry, Medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Experiment study on hydroxyapatite bone cement as a slow-release carrier of bioactive factor — Research Paper | ScholarLens